Search

Background: Both primary care physicians (PCPs) and endocrinologists (Endos) commonly prescribe T2D medications. This study presents real-world effectiveness of sema OW by prescriber specialty in a cohort of US commercially insured/Medicare Advantage T2D patients newly initiating a GLP-1 agonist. Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 12/1/17 - 6/30/20 (index as first claim). Selected patients had ≥1 A1c result within ≤3 months pre and ≥3 months post-index. Patients with no claim for any GLP-1 agonist in the 12 months pre-index and persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c) were assessed for A1c changes stratified by prescriber specialty (PCPs/Endos) and by pre-index A1c >9%. Results: A1c was significantly reduced vs. pre-index in 1,284 patients prescribed sema OW by a PCP or Endo (both -1.3%; p 9% (both -2.8%; p Conclusion: Similar pre/post reductions in A1c were observed when initiating sema OW in T2D GLP-1 agonist naive patients being treated by PCPs and Endos. Disclosure N. Shivappa: Other Relationship; Self; Novo Nordisk. J. Noone: Employee; Self; Novo Nordisk Inc. C. Swift: Employee; Self; Novo Nordisk Inc. S. Du: None. H. Tan: Other Relationship; Self; HealthCore. Y. M. Paprocki: Employee; Self; Novo Nordisk, Stock/Shareholder; Self; Novo Nordisk. V. Willey: Employee; Self; HealthCore.

Background: With OS’s FDA approval in September 2019, this study sought to provide real-world evidence on its effectiveness in a cohort of early users. Methods: Claims and lab result data were used to identify T2D patients who initiated OS between 09/20/19 - 10/31/20 (first claim date set as index). Selected patients had ≥1 HbA1c result within both ≤3 months pre- and ≥3 months post-index and ≥ 12 months pre-index health plan eligibility. Study groups included: all patients, patients persistent on OS (those with a OS prescription within 1.5 times of days supply dispensed overlapping/in proximity to most recent post-index HbA1c), GLP-1 naive patients, and patients with a pre-index HbA1c >9%. Results: Of the 323 individuals with T2D initiating OS, 42.4% were female with a mean age of 55 years and 77% were GLP-1 naive. Mean HbA1c was significantly reduced in all patients (-0.9%) and subgroups (all p Conclusions: OS initiation was associated with a significant reduction in HbA1c and increase in HbA1c goal attainment in real-world practice in this preliminary cohort. Disclosure N. Shivappa: Other Relationship; Self; Novo Nordisk. C. Swift: Employee; Self; Novo Nordisk Inc. J. Noone: Employee; Self; Novo Nordisk Inc. S. Du: None. M. Radin: Employee; Self; Novo Nordisk Inc. C. Gamble: Employee; Self; Novo Nordisk Inc. H. Tan: Other Relationship; Self; HealthCore. V. Willey: Employee; Self; HealthCore.

Background: This study presents real-world evidence on effectiveness of sema OW in a broad cohort of US commercially insured and Medicare Advantage T2D patients. Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 12/1/17 - 6/30/20 (index as first claim). Selected patients had ≥1 A1c result within ≤3 months pre- and ≥3 months post-index. Patients persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c measurement) were assessed for A1c changes and stratified by age ( 9%. Results: 3,010 patients initiated sema OW, 49% were female and 10% were ≥ 65 years of age. A1c was significantly reduced vs. pre-index in all persistent patients (-1.1%) and in each age subgroup ( 9%. Attainment of A1c Conclusion: In this broad, real-world cohort of US T2D patients, initiation of sema OW was associated with significant reduction in A1c and an increase in reaching an A1c Disclosure V. Willey: Employee; Self; HealthCore. N. Shivappa: Other Relationship; Self; Novo Nordisk. J. Noone: Employee; Self; Novo Nordisk Inc. C. Swift: Employee; Self; Novo Nordisk Inc. S. Du: None. Y. M. Paprocki: Employee; Self; Novo Nordisk, Stock/Shareholder; Self; Novo Nordisk. H. Tan: Other Relationship; Self; HealthCore.

Background: This study presents real-world effectiveness of sema OW in a cohort of US commercially insured/Medicare Advantage T2D patients newly initiating a GLP-1 agonist. Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 12/1/17 - 6/30/20 (index as first claim). Selected patients had ≥1 A1c result within ≤3 months pre- and ≥3 months post-index. Patients with no claim for any GLP-1 agonist in the 12 months prior to index and persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c) were assessed for A1c changes and stratified by age ( 9%. Results: Of 1,842 patients newly initiating sema OW, 49% were female and 8% were ≥ 65 years of age. The pre/post change in A1c was significant in all patients (-1.3%) and in each age subgroup ( 9%, regardless of age. Attainment of A1c Conclusion: nitiation of sema OW in T2D patients naive to GLP-1 agonists and persistent on sema OW was associated with a significant reduction in A1c and an increase in target attainment of A1c Disclosure N. Shivappa: Other Relationship; Self; Novo Nordisk. C. Swift: Employee; Self; Novo Nordisk Inc. J. Noone: Employee; Self; Novo Nordisk Inc. S. Du: None. Y. M. Paprocki: Employee; Self; Novo Nordisk, Stock/Shareholder; Self; Novo Nordisk. H. Tan: Other Relationship; Self; HealthCore. V. Willey: Employee; Self; HealthCore.

Antidiabetic medication (med) treatment patterns often differ based on a variety of patient and prescriber factors. Understanding these patterns may provide insight on optimizing therapy, especially when considering initiation of a new therapy. This study presents real-world evidence on T2D treatment patterns associated with sema OW initiation within a large cohort of T2D patients. Methods: Claims and lab result data were used to identify T2D patients from a US commercially insured/Medicare Advantage population who initiated sema OW between 12/1/17 - 6/30/20 (index as 1st claim). Selected patients had continuous health plan enrollment for ≥ 2 years pre-index and post-index through at least 90 days after the last available A1c value. Antidiabetic meds prescribed before, at the time and after initiation of sema OW were evaluated overall and for those with an A1c >9%. Results: A total of 3,081 T2D patients were identified, of which 865 patients had A1c >9%. Sema OW was initiated down the treatment pathway, with ~60% on ≥2 and ~30% on 3+ T2D meds at sema OW initiation. Sema OW was an add-on therapy to most T2D med classes overall, although when initiated onto more complex therapy regimens it was more likely to be a therapy switch (T2D monotherapy = 24% switched to sema OW, dual therapy = 46%, triple therapy = 64%, 4+ T2D medications = 70%). Following post-index A1c measurement, 35% of patients overall and 29% with a baseline A1c >9% decreased the number of their T2D meds. Conclusion: Sema OW appeared to be initiated as add-on therapy, except for those on more complex regimens. Approximately 1/3 of patients decreased their overall T2D med use after evaluation of A1c following sema OW initiation. Further research is warranted to assess impact of initiating sema OW earlier in the T2D treatment pathway, especially in patients with cardiovascular and chronic kidney disease. Disclosure V. Willey: Employee; Self; HealthCore. N. Shivappa: Other Relationship; Self; Novo Nordisk. C. Swift: Employee; Self; Novo Nordisk Inc. J. Noone: Employee; Self; Novo Nordisk Inc. S. Du: None. Y. M. Paprocki: Employee; Self; Novo Nordisk, Stock/Shareholder; Self; Novo Nordisk. H. Tan: Other Relationship; Self; HealthCore.

Background: This study presents real-world evidence on effectiveness of sema OW in a large cohort of T2D patients. Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 2/1/18 - 4/30/19 (index as first claim). Patients selected had ≥1 A1c result within ≤3 months pre- and ≥3 months post-index. All patients and a group of patients persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c measurement) were assessed for A1c changes and were split into 4 subgroups: GLP-1 naïve, GLP-1 experienced and either group with pre-index A1c >9%. Results: Of 1,888 patients initiating sema OW, 57.8% were GLP-1 naïve. A1c was significantly reduced in all patients (-0.9%) and subgroups (p Conclusion: Initiation of sema OW was associated with significant reduction in A1c and an increase in reaching A1c Disclosure J. Visaria: None. C. Uzoigwe: Employee; Self; Novo Nordisk Inc. C. Swift: Employee; Self; Novo Nordisk Inc. Stock/Shareholder; Self; Novo Nordisk Inc. Y.M. Paprocki: Employee; Self; Novo Nordisk Inc. Stock/Shareholder; Self; Novo Nordisk A/S. V. Willey: Employee; Self; HealthCore. Funding Novo Nordisk

Background: With semaglutide’s FDA approval in Dec 2017, this study sought to provide real-world evidence on its effectiveness in a cohort of early users. Methods: Claims and lab result data from a broad national U.S. CI and MA population were used to identify T2DM patients who initiated semaglutide between 12/1/17 - 6/30/18 (first claim date set as index). Of these, patients who had ≥12-month pre-index health plan eligibility as well as ≥1 HbA1c result within both ≤3 months pre- and ≥3 months post-index were selected. Changes in HbA1c were assessed in all patients, GLP-1 naïve patients and GLP-1 naïve patients with a pre-index HbA1c >9%. Results:Of 107 individuals with T2DM initiating semaglutide, 48.6% were female with median age of 52 years. HbA1c was significantly reduced in all patients (-1.3%), GLP-1 naïve patients (-2.0%) and HbA1c >9% GLP-1 naïve patients (-2.9%) (all p9% GLP-1 naïve) (all p Conclusions: Semaglutide initiation was associated with a significant reduction in HbA1c and increase in HbA1c goal attainment in real-world practice in this preliminary T2DM cohort. Ongoing research will include a broader group of semaglutide users as well as allow for longer post-initiation follow-up to fully assess its effect. Disclosure J. Visaria: Employee; Self; HealthCore. T. Dang-Tan: Employee; Self; Novo Nordisk Inc. P.V. Petraro: Employee; Self; Novo Nordisk Inc. B.K. Nepal: None. V. Willey: Employee; Self; HealthCore. Funding Novo Nordisk